Can a patient currently taking apixaban (Eliquis) switch to dabigatran (Pradaxa) after completing the current Eliquis prescription?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, switching from Eliquis (apixaban) to Pradaxa (dabigatran) is safe and straightforward after finishing the current Eliquis prescription.

The patient can simply stop Eliquis and start Pradaxa at the time of the next scheduled Eliquis dose—no bridging anticoagulation or waiting period is required 1, 2.

How to Switch from Eliquis to Pradaxa

Direct Transition Protocol

  • Discontinue Eliquis and begin Pradaxa at the usual time of the next scheduled Eliquis dose 1
  • No bridging therapy with heparin or other anticoagulants is needed 1
  • No washout period is required between stopping one DOAC and starting another 1

Pradaxa Dosing Considerations

The appropriate Pradaxa dose depends on the indication and patient factors 2:

For Atrial Fibrillation:

  • Standard dose: 150 mg twice daily
  • Reduced dose: 110 mg twice daily if:
    • Age ≥80 years, OR
    • Taking verapamil concurrently

For VTE Treatment:

  • 150 mg twice daily (requires 5-10 days of parenteral anticoagulation first for acute VTE) 2
  • If already on Eliquis for established VTE, can switch directly to 150 mg twice daily

Renal Function Matters:

  • If creatinine clearance 30-50 mL/min: Consider dose reduction or avoid dabigatran 2
  • If creatinine clearance <30 mL/min: Avoid dabigatran 2

Important Caveats

Check Renal Function First

Dabigatran is 80% renally eliminated compared to apixaban's 27% renal elimination 3. Before switching, verify the patient's creatinine clearance to ensure dabigatran is appropriate. This is the most critical safety consideration when moving from Eliquis to Pradaxa.

Gastrointestinal Considerations

Dabigatran has higher rates of dyspepsia and potentially more GI bleeding than apixaban 4. If the patient has a history of GI issues, this may not be the ideal cost-saving switch. Consider discussing this trade-off with the patient.

Cost vs. Clinical Appropriateness

While cost is a legitimate concern, switching anticoagulants purely for financial reasons should still involve clinical assessment. Real-world data suggests apixaban may have lower switch rates and potentially fewer adverse events compared to dabigatran 5, 6, though switching between DOACs appears generally safe when done appropriately 7.

Practical Implementation

  1. Verify renal function (calculate CrCl using Cockcroft-Gault formula)
  2. Confirm indication (atrial fibrillation vs. VTE) to determine correct Pradaxa dose
  3. Patient takes last Eliquis dose (e.g., morning dose)
  4. Start Pradaxa at next scheduled time (e.g., that evening if Eliquis was twice daily)
  5. Counsel patient about taking Pradaxa with full glass of water, swallowing capsules whole, and potential for dyspepsia 2

The switch is medically straightforward and supported by FDA labeling for both medications, making this a reasonable cost-saving strategy if the patient's renal function is adequate.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.